文献速递其他结缔组织病

成人特发性炎性肌病相关间质性肺病的预后:679例回顾性研究

Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该回顾性研究纳入679例成人特发性炎性肌病(IIM)患者,其中508例合并间质性肺病(ILD)。ILD患病率在临床无肌病性皮肌炎、皮肌炎和多发性肌炎组分别为92.7%、73.6%和55.1%(P<0.01)。抗合成酶抗体(ASA)阳性组ILD患病率高于阴性组(95.2% vs 72.4%,P<0.01),MDA-5抗体阳性组也高于阴性组(97.8% vs 72.1%,P<0.01)。

要点

  • IIM患者中ILD患病率因临床亚型和抗体状态而异。
  • 临床无肌病性皮肌炎和皮肌炎合并ILD者全因死亡率高于多发性肌炎合并ILD者。
  • MDA5+ASA-的IIM-ILD患者全因死亡率高于MDA5-ASA-和MDA5-ASA+组。

核心结论

  • IIM中ILD的患病率及IIM-ILD患者的预后可能因ASA和MDA-5抗体状态而异。

研究设计与样本

  • 回顾性分析2012年1月至2017年12月诊断为IIM的患者,注册760例IIM中纳入679例成人病例。

主要发现

  • ILD在临床无肌病性皮肌炎、皮肌炎和多发性肌炎组的患病率分别为92.7%、73.6%和55.1%(P<0.01)。
  • ASA+IIM组ILD患病率高于ASA-组(95.2% vs 72.4%,P<0.01),Jo-1+与Jo-1-ASA+组间无差异(93.0% vs 98.5%,P>0.05)。
  • MDA-5+IIM组ILD患病率高于MDA-5-组(97.8% vs 72.1%,P<0.01)。
  • 合并ILD的老年(>50岁)男性IIM患者死亡风险最高。
  • 皮肌炎-ILD与临床无肌病性皮肌炎-ILD组全因死亡率无显著差异(33.3% vs 23%,P>0.05),但均高于多发性肌炎组(13.2%,P=0.01和P<0.05)。

关键数值与推荐

  • ILD患病率:临床无肌病性皮肌炎92.7%,皮肌炎73.6%,多发性肌炎55.1%(P<0.01)。
  • ILD患病率:ASA+组95.2% vs ASA-组72.4%(P<0.01);MDA-5+组97.8% vs MDA-5-组72.1%(P<0.01)。
  • 全因死亡率:皮肌炎-ILD组33.3% vs 临床无肌病性皮肌炎-ILD组23%(P>0.05),均高于多发性肌炎组13.2%(P=0.01和P<0.05)。
  • 全因死亡率:MDA5-ASA-组17.2% vs MDA5-ASA+组12.8%(P>0.05),均低于MDA5+ASA-组33.7%(P<0.05)。

临床怎么用

  • 对IIM患者应结合临床亚型及ASA、MDA-5抗体状态评估ILD风险及预后。
  • 对合并ILD的老年男性IIM患者需加强病情监测。

局限性

  • 回顾性研究设计可能引入选择偏倚和信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Few studies have investigated the prognostic factors for idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD) across different clinical/serological phenotypes. METHODS: We conducted a retrospective analysis of patients diagnosed with IIM between January 2012 and December 2017. RESULTS: Of the 760 IIM cases registered, 679 adult cases were included in this study. ILD was present in 508 cases, and the presence of ILD in the clinically amyopathic DM, DM and PM groups was 92.7, 73.6 and 55.1%, respectively (P < 0.01). The prevalence of ILD in the anti-synthetase antibody (ASA)+-IIM group was higher than that in ASA--IIM group (95.2 vs 72.4%, P < 0.01); no such difference was found between the anti-histidyl-tRNA synthetase (Jo-1)+-IIM and Jo-1-ASA+-IIM groups (93.0 vs 98.5%, P > 0.05). The prevalence of ILD in the melanoma differentiation-associated protein-5 (MDA-5)+-IIM group was higher than that in MDA-5--IIM group (97.8 vs 72.1%, P < 0.01). Among adults with IIM, men with concurrent ILD, who were older than 50 years, were most likely to die. No significant difference was found in the all-cause mortality rates between DM-ILD and clinically amyopathic DM-ILD groups (33.3 vs 23%, P > 0.05), although both were higher than that in PM group (13.2%, P = 0.01 and P < 0.05, respectively). No difference was found in the all-cause mortality rates between MDA5-ASA--IM-ILD and MDA5-ASA+-IM-ILD groups (17.2 vs 12.8%, P > 0.05), and both were lower than that in MDA5+ASA--IM-ILD group (33.7%, P < 0.05). CONCLUSION: The prevalence of ILD in IIM and the prognosis of IIM-ILD patients may vary depending on the statuses of the ASA and MDA-5 antibodies.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Li S, Sun Y, Shao C, et al. Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases. Rheumatology (Oxford). 2021. PMID: 32894294. doi:10.1093/rheumatology/keaa372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。